Table 3.
Experimental Group | Control Group | E vs. C p-value1 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | Post | Baseline | Post | ||||||||
n | %* | n | %* | Chg | n | %* | n | %* | Chg | ||
Overall CPPI: mean | 202 | 32.5 | 166 | 34.1 | +1.6 | 197 | 30.8 | 171 | 34.1 | +3.3 | 2 |
COMPREHENSIVE ADMISSION ASSESSMENT | |||||||||||
Individual CPPI Indicators | |||||||||||
1. Valid pain scale use at admission | 202 | 67.3 | 168 | 86.9 | +19.6 | 197 | 72.1 | 171 | 83.0 | +10.9 | 0.16 |
2. Comprehensive assessment- primary (Pain Intensity, Pain Location, Pain Quality, Pain Duration/Pattern, Impact of Pain on Function) | 175 | 67.0 | 159 | 67.9 | +0.9 | 178 | 67.0 | 157 | 76.3 | +9.3 | 0.21 |
3. Comprehensive assessment- other (Detailed Pain history including description of previous & current pain episodes & treatment effectiveness; Physical exam- including musculoskeletal & neurological assessment; Presence or absence of delirium; Things that make pain better; Things that make pain worse; and Presence of Anxiety and Depression | 175 | 13.1 | 159 | 11.5 | −1.6 | 178 | 16.5 | 157 | 16.7 | +0.2 | 0.67 |
4. Reports of moderate/severe (≥ 5) pain followed by pain severity reassessment within 24 hours | 47 | 12.2 | 44 | 16.7 | +4.5 | 48 | 8.2 | 45 | 15.2 | +7 | 0.62 |
5. Increases in pain medications for consecutive reports of pain severity 5 or greater within 24 hrs | 19 | 32.9 | 19 | 49.1 | +16.2 | 19 | 17.5 | 22 | 33.3 | +15.8 | 0.81 |
6a. Patients with admission report of pain as mild (1–4) with order for nonopioid or combination of opioid- nonopioid analgesic within 24 hours of admission (Items 6a & 6b combined on CPPI) | 30 | 73.3 | 31 | 90.3 | +17 | 32 | 81.3 | 53 | 88.7 | +7.4 | 0.51 |
6b. Pts. with admission report of pain as moderate (5–6) or < with order for opioid analgesic within 24 hours of admission (Items 6a & 6b combined on CPPI) | 33 | 90.9 | 30 | 96.7 | +5.8 | 26 | 92.3 | 23 | 95.7 | +3.4 | 0.79 |
7. Pts. with opioid order with bowel regimen initiated (includes both laxative & stool softener) | 172 | 33.7 | 160 | 35.0 | +1.3 | 175 | 30 | 150 | 32.0 | +2 | 0.94 |
8. Pts. with opioids ordered who were monitored each day; a focused assessment is completed for the five most common analgesic-induced side effects (1. Respiratory depression, 2. Sedation, 3. Nausea and vomiting, 4. Constipation, 5. Delirium) | 172 | 19.2 | 160 | 19.2 | 0 | 175 | 19.4 | 150 | 17.3 | −2.1 | 0.71 |
9. Non-pharmacologic therapies used | 182 | 39 | 162 | 50.6 | +11.6 | 182 | 11 | 159 | 37.1 | +26.1 | 0.00 |
10. Focused assessments that include a review of the Pain Management Plan (PMP) | 179 | 59.9 | 157 | 49.1 | −10.8 | 177 | 61.2 | 157 | 53.3 | −7.9 | 0.69 |
11. Pts. with documentation of a written pain management plan | 127 | 26.2 | 143 | 20.8 | −5.4 | 166 | 39.3 | 149 | 28.4 | −10.9 | 0.57 |
An individual CPPI score is presented as a % of applicable EBPs a patient received. The higher the % the more EBPs received.
The p-values were obtained from logistic regression model using contrast Experimental Post Intervention (EPI) – Experimental Baseline (EB) –Control Post Intervention (CPI) – Control Baseline (CB), where each indicator (0 or 1) was treated as the response variable and intervention (4 categories: EPI, EB, CPI, and CB) was the only independent variable.
p-value calculated from GEE final model is reported in Table 4